Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 50%GRADE not reported 0 · 0%Very low 2 · 25%Low 0 · 0%Moderate 2 · 25%High 0 · 0%

Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone

Mortality ‐ early and intermediate · people requiring treatment for acute DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 500 participants
Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone

Mortality ‐ early and intermediate · people requiring treatment for chronic DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 224 participants
Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Mortality ‐ intermediate and long term · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.48 [0.21, 1.06]
3 studies · 649 participants
Moderate

Aspirin vs placebo

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ASA with LMWH vs placebo or IVIG

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant with or without ASA vs ASA only

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs antiplatelet agent

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Moderate